43 results about "Thymic stromal lymphopoietin" patented technology

The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

The invention provides an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an application thereof. The anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), and (a) the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, and (b) the amino acid sequence of CDR-H2 is as shown in SEQ ID NO: 2; (c) the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3; (d) the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4; (e) the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5; and the amino acid sequence of the (f) CDR-L3 is as shown in SEQ ID NO: 6. Compared with an anti-human TSLP monoclonal antibody Tezepelumab (prepared according to sequence expression disclosed in the patent), the anti-human TSLP monoclonal antibody has the advantages that the affinity of the anti-human TSLP monoclonal antibody combined with the human TSLP is equivalent, the neutralizing activity of the anti-human TSLP monoclonal antibody at the cellular level is superior to that of the Tezepelumab, and the anti-human TSLP monoclonal antibody is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.

The invention provides a bispecific antibody against human thymic stromal lymphopoietin (TSLP), a monoclonal antibody and uses of the bispecific antibody and the monoclonal antibody.

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

The invention relates to application of calycosin in pharmacy, in particular to application of calycosin in treatment of anaphylactic diseases. The calycosin which is a main active ingredient for treatment of the anaphylactic diseases has no evident toxic or side effects on immune organs and other cells and is capable of effectively inhibiting generation and secretion of TSLP (thymic stromal lymphopoietin), IL-25 (interleukin-25) and IL-33 (interleukin-33) in core links of the anaphylactic diseases and expected to be a high-efficiency low-toxicity medicine for treatment of the anaphylactic diseases.

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

The present invention relates to a pharmaceutical composition, a cosmetic composition, or a health functional food, which are capable of effectively alleviating allergic diseases by inhibiting the secretion of Thymic stromal lymphopoietin (TSLP) and inhibiting TSLP, and which include, as an active ingredient, a compound represented by chemical formula 1 of the present invention or a pharmaceutically acceptable salt. Accordingly, the composition has an excellent effect for inhibiting the secretion of TSLP, which is an immune reaction factor, and thus is superior for alleviating allergic diseases caused by an imbalance in the immune system.

The present invention provides a liquid composition comprising a monoclonal antibody against thymic stromal lymphopoietin. The liquid composition contains the monoclonal antibody at a high concentration, the antibody can be kept stable for a long time, and a preparation has appropriate viscosity and osmotic pressure and can be used as a subcutaneous injection preparation. In addition, the invention further provides application of the liquid composition in preparation of drugs for treating diseases or symptoms related to TSLP signal transmission and / or TSLP high expression. The invention further provides a container comprising the liquid composition and a medicine box comprising the container.

Provided are methods for treating a TSLP-mediated or TSLPR-mediated disease or condition, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating a TSLP-mediated or TSLPR-mediated disease or condition. The charge-stabilized oxygen-containing nanostructures are preferably stably configured in the fluid in an amount sufficient to provide for modulation of cellular membrane potential and / or conductivity. Certain aspects comprising modulation or down-regulation of TSLP expression and / or activity have utility for treating TSLP-mediated or TSLPR-mediated diseases or conditions as disclosed herein (e.g., disorders of the immune system, allergic inflammation, allergic airway inflammation, DC-mediated inflammatory Th2 responses, atopic dermatitis, atopic eczema, asthma, obstructive airways disease, chronic obstructive pulmonary disease, and food allergies, inflammatory arthritis, rheumatoid arthritis, psoriasis, IgE-mediated disorders, and rhino-conjunctivitis).

The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.

The invention discloses a liquid preparation of an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody. The liquid preparation comprises an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an amino acid protection agent, wherein the protein concentration of the anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody is 100-300mg / ml, the amino acid concentration of the amino acid protection agent is 10-500mM, the monoclonal antibody comprises three heavy chain complementarity determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementarity determining regions (CDR-L1, CDR-L2 and CDR-L3), the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and the amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. The liquid preparation disclosed by the invention is relatively low in viscosity and can be easily injected by a syringe, so that the liquid preparation can be used as an injection, especially a hypodermic injection.

The present invention relates to a cosmetic composition for inhibiting and relieving pruritus or alleviating atopic dermatitis, containing, as an active ingredient, isosecotanapartholide represented by chemical formula [1] below. According to the present invention, the cosmetic composition containing isosecotanapartholide is very safe since cytotoxicity has not been observed, is capable of inhibiting and relieving pruritus by inhibiting interleukin-31 (IL-31) or interleukin-33 (IL-33) among cytokines causing various types of pruritus, has an excellent ability of inhibiting a thymic stromal lymphopoietin (TSLP) cytokine, which is the top-level protein in abnormal signaling caused by an immune imbalance, which is the fundamental cause of atopic dermatitis, and has an excellent ability of inhibiting the expression of MDC and TARC chemokines in HaCaT cells, and thus the cosmetic composition can alleviate atopic skin.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.

A composition according to an embodiment includes porous silica particles carrying nucleic acid molecules that complementarily bind to at least a portion of thymic stromal lymphopoietin (TSLP) mRNA. The composition is capable of preventing or treating, with excellent efficiency, atopic diseases, such as bronchial asthma, allergic rhinitis, atopic dermatitis, allergic dermatitis or inflammatory skin diseases by effectively inhibiting the expression level of TSLP.

The invention relates to the technical field of antibodies, in particular to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody provided by the present invention can specifically bind hTSLP with high affinity, and can effectively inhibit the binding of TSLP to its receptor, thereby inhibiting TSLP from activating downstream signaling pathways and activating immune cells. The TSLP antibody provided by the present invention is used for the content detection of hTSLP and allergic asthma, chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic sinusitis, eosinophilic esophagitis, allergic conjunctivitis, inflammatory bowel disease It is of great significance in the diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as atopic dermatitis or atopic dermatitis.

The invention discloses application of sinomenine in preparation of a drug for treating photosensitive dermatitis. The drug disclosed by the invention has an obvious effect for treating the photosensitive dermatitis. The treatment effect of the drug disclosed by the invention on the photosensitive dermatitis is closely related to the effect of decreasing TSLP (Thymic stromal lymphopoietin)-DCs induced T-lymphocyte toxic damage.